^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
minocycline
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Generic mfg.
Drug class:
Immunomodulator, Protein synthesis inhibitor, IL-1α inhibitor, IL-6 modulator
Related drugs:
1d
A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants (clinicaltrials.gov)
P1/2, N=33, Recruiting, TenNor Therapeutics Inc. | Trial completion date: Jan 2026 --> Aug 2026 | Trial primary completion date: Jan 2026 --> Aug 2026 | Completed --> Recruiting
Enrollment open • Trial completion date • Trial primary completion date
|
minocycline
3d
A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants (clinicaltrials.gov)
P1/2, N=9, Completed, TenNor Therapeutics Inc. | Recruiting --> Completed | N=33 --> 9 | Trial completion date: Aug 2026 --> Jan 2026 | Trial primary completion date: Aug 2026 --> Jan 2026
Trial completion • Enrollment change • Trial completion date • Trial primary completion date
|
minocycline
15d
Effect of Arestin-Enhanced SRP on Periodontal and Glycemic Outcomes in Diabetics (clinicaltrials.gov)
P1, N=42, Recruiting, Case Western Reserve University | Not yet recruiting --> Recruiting
Enrollment open
|
minocycline
22d
Fecal Molecular Susceptibility-guided Hp Rescue Therapy (clinicaltrials.gov)
P4, N=290, Not yet recruiting, Shanghai Zhongshan Hospital
New P4 trial • HEOR
|
minocycline
22d
Fecal Molecular Susceptibility-guided Hp First-line Therapy (clinicaltrials.gov)
P4, N=544, Not yet recruiting, Shanghai Zhongshan Hospital
New P4 trial • HEOR
|
minocycline
26d
Microglia alter autonomic nuclei neuronal activation after peripheral cytokine challenge. (PubMed, Am J Physiol Cell Physiol)
When animals were challenged with TNFα after receiving minocycline, fewer c-Fos-positive cells were induced in the DVC and selectively in the rostral VLM. These findings highlight the spatial selectivity of cells in the brainstem to increased peripheral pro-inflammatory signaling, as well as the impact of resident microglia on autonomic circuitry responses.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • FOS (Fos Proto-Oncogene AP-1 Transcription Factor Subunit 2)
|
minocycline
30d
Endothelial oncogenic KRAS mutation drives the dynamics of microglia and macrophages in brain arteriovenous malformation. (PubMed, JCI Insight)
Inhibition of MG/Mϕ with long-term minocycline treatment attenuated the incidence of ICHs around bAVMs. Our study indicates that MG/Mϕ are involved in destabilization of KRAS-induced bAVM, leading to hemorrhagic conversion/ICH. Thus, modulation of MG/Mϕ may reduce ICH risk in bAVM patients.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • CCR2 (C-C Motif Chemokine Receptor 2) • CX3CR1 (C-X3-C Motif Chemokine Receptor 1)
|
KRAS mutation • KRAS G12
|
minocycline
1m
Efficacy and Safety of Keverprazan-Minocycline Dual Therapy Versus Bismuth-Containing Quadruple Therapy for First-Line Eradication of Helicobacter pylori Infection: A Prospective Multicenter Randomized Controlled Trial (ChiCTR2600116736)
P=N/A, N=340, Not yet recruiting, Northern Jiangsu People's Hospital; Northern Jiangsu People's Hospital
New trial
|
minocycline
1m
Diagnosis and Treatment of Refractory Complex Skin Diseases: A Single-center, Prospective, Open-label, Non-randomized, Self-controlled Clinical Study Evaluating the Safety and Efficacy of Topical Minocycline for EGFR Inhibitor-Induced Cutaneous Adverse Reactions (ChiCTR2600116706)
P=N/A, N=60, Not yet recruiting, Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University; Provincial People's Hospital (Guangdong Academy of
New trial
|
minocycline
1m
Effect analysis and mechanism study of Abrocitinib in the treatment of bullous pemphigoid (ChiCTR2500114958)
P=N/A, N=30, Completed, Peking University First Hospital; Peking University First Hospital
New trial
|
minocycline
1m
Efficacy and Safety of Minocycline in the Treatment of Intracerebral Hemorrhage: a multicenter, randomized, open-label, blinded endpoint clinical study (ChiCTR2500114607)
P=N/A, N=1248, Not yet recruiting, The First Hospital of Jilin University; The First Hospital of Jilin University
New trial
|
minocycline
1m
Efficacy and Safety of Minocycline in Patients with Acute Spontaneous Intracerebral Hemorrhage (ChiCTR2600117240)
P4, N=1192, Not yet recruiting, Beijing Tiantan Hospital, Capital Medical University; Beijing Tiantan Hospital, Capital Medical University
New P4 trial
|
minocycline
Share via
